Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Y-mAbs Therapeutics (YMAB) Misses Q4 EPS by 58c
February 24, 2022 4:33 PM ESTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($1.28), $0.58 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $10.82 million.
The Company had approximately $181.6 million in cash and cash equivalents as of December 31, 2021.
For earnings... More
